Appili Therapeutics Inc. announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appilis Chief Development Officer. Dr. Nabors joins Appili effective April 3, 2023, and will lead the advancement of programs through development, regulatory submission and key commercialization milestones. Garys expertise in infectious disease will be instrumental in driving forward the development of programs; ATI-1701, a vaccine for tularemia being funded by the U.S. Government through IND submission and ATI-1801, a treatment for cutaneous leishmaniasis (CL), a disfiguring infection of the skin.

Dr. Nabors joins Appili from Integrated BioTherapeutics Inc. (IBT) where, in his role as Executive Vice President and Chief Development Officer, he was responsible for leading the companys vaccine and immunotherapeutic candidates through bioanalytical development, IND-enabling studies, GMP manufacturing and into clinical studies. Prior to that he served as President of DynPort Vaccine Company Inc. (a subsidiary of General Dynamics) where he was responsible for the overall success of the company, overseeing P&L responsibility and 800 staff, and establishing the technical, strategic, and regulatory direction for all projects in the companys portfolio. Over his accomplished 25-year career, Dr. Nabors has also held progressively senior roles with Sanofi Pasteur, Emergent BioSolutions, and the National Biodefense Analysis and Countermeasures Center (NBACC) within the U.S. Department of Homeland Security.

He has played a central role in product development from pre-clinical stages through to Phase 3, for development of vaccines and therapeutics for pediatric, adult, and biodefense markets. He has also managed corporate subsidiaries of 120 employees, served on executive-level management committees and presented before Food and Drug Administration (FDA) advisory committees. Dr. Nabors will be representing Appili at the World Vaccine Congress, the premier event for R&D and strategic partnering for the global vaccine industry, in Washington, D.C., from April 3rd to 6th, 2023.

Dr. Nabors will be participating in scientific sessions to identify current trends in vaccine development and to network with key contacts that Appili may be able to work with to help advance its programs.